NOTICE OF UPGRADE
Our websites will be unavailable between the hours of AEST 4AM September 17, 2022 and AEST 11PM on date September 18, 2022
SEARCH LISTED COMPANY
Any AUS or NZ company
SEARCH PRIVATE COMPANY
SEARCH FUNDS
Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
|
|
25 April 2025
| Name: | VIRAX HOLDINGS LIMITED (VHL) (This company subsequently changed its name to PRESCIENT THERAPEUTICS LIMITED. You should refer to that name for Status.) | ||||||
| Date of Listing: | 19 December 1986 | ||||||
| Subsequent Names: |
| ||||||
| Former Names: |
|
Stock Exchange Status: (updated daily)
This company subsequently changed its name to PRESCIENT THERAPEUTICS LIMITED. You should refer to that name for Stock Exchange Status.Legal Status: (updated monthly)
This company subsequently changed its name to PRESCIENT THERAPEUTICS LIMITED. You should refer to that name for Legal Status.Capital Gains Tax (CGT) Status: (updated at least quarterly)
This company subsequently changed its name and is now PRESCIENT THERAPEUTICS LIMITED. You should refer to that name for Capital Gains Tax Status.
Updates, corrections, disagreements please email to admin@delisted.com.au
Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.
Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.
Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.
| FROM | TO | |
| PRESCIENT THERAPEUTICS LIMITED | 15/12/2014 | |
| VIRAX HOLDINGS LIMITED | 24/03/1997 | 15/12/2014 |
| RANCOO LIMITED | 24/03/1997 |
Computershare Melbourne
Yarra Falls, 452 Johnston Street, Abbotsford VIC 3067
Tel : +61 (0)3 9415 4000 or 1300 850 505 (within Australia)
Fax : +61 3 9473 2500
RegistryWebsite RegistryEmail
Expand this box to read and print
name changed to Prescient Therapeutics Limited | 15/12/2014 |
The securities of Virax Holdings Limited (the "Company") will be reinstated to official quotation at the commencement of trading on Tuesday, 19 November 2013 following effectuation of the deed of company arrangement and completion of a capital raising. Security Code: VHL | 18/11/2013 |
releases Annual Report for the Year Ended 30 June 2013, Half Yearly Report for the period ended 31 December 2012 and Annual Report for the Year Ended 30 June 2012 | 14/11/2013 |
company is no longer in administration | 13/11/2013 |
in accordance with the Prospectus dated 19 September 2013, the Company has had significant interest in the capital raising and has received subscriptions well in excess of the proposed maximum $2,500,000 capital raising | 25/10/2013 |
issues a prospectus for the offer of 25 million First Placement Shares at an issue price of $0.00001 per Share to raise $250 and 100 million First Placement Options at an issue price of $0.00001 per First Placement Option to raise $1,000 (together the First Placement) and For the offer of a minimum of 360,000,000 Second Placement Shares and up to a maximum of 140,000,000 additional Second Placement Shares, at an issue price of $0.005 per Share to raise at least $1,800,000 or up to a maximum of $2,500,000 | 19/09/2013 |
it is our understanding a share consolidation is about to take place whereby 10 existing shares are consolidated into one share | 03/09/2013 |
executes a reconstruction deed | 26/02/2013 |
the company is to enter into a Deed of Company Arrangement | 12/10/2012 |
Directors today appointed Mr. Laurie A Fitzgerald and Mr. Stephen R Dixon of Grant Thornton as Voluntary Administrators of the Company | 24/08/2012 |
The directors of the Company request the continuation of the suspension of the Company's securities from official quotation. The Company is to make an announcement shortly concerning the termination of the Share Sale Agreement with the vendors of 4G Vaccines Pty Ltd | 14/06/2012 |
provides an update on Transgene" clinical program TG4001 (HPV therapeutic vaccine). This project utilises Co-X-GeneTM technology and is the subject of a license agreement between Transgene and Virax | 14/05/2012 |
at the Noteholder General Meeting of Virax Holdings Limited the resolutions to amend to terms of the Convertible Notes were passed | 30/03/2012 |
releases copies of the Notice of Meeting, Proxy Form and Information Memorandum for the Noteholder General Meeting to be held on Friday 30 March 2012 at Quest Beaumont Kew, 7 Studley Park Road, Kew at 2.00 pm - ASX Code - VHLG | 15/03/2012 |
suspended following failure to lodge financial reports | 01/03/2012 |
the unsecured convertible notes (the "Notes") of Virax Holdings Limited (the "Company") will be suspended from quotation at the close of trading on 21 December 2011, pending their maturity on 31 December 2011. For details of a proposal to extend the maturity date of the Notes to 31 March 2012, please refer to the Company's notice of meeting lodged on ASX on 12 December 2011. Security Code: VHLG Please note the suspension only applies to the Notes and not to the Company's other quoted securities | 21/12/2011 |
name changed from Rancoo Limited | 24/03/1997 |
name changed to Prescient Therapeutics Limited | 15/12/2014 |
The securities of Virax Holdings Limited (the "Company") will be reinstated to official quotation at the commencement of trading on Tuesday, 19 November 2013 following effectuation of the deed of company arrangement and completion of a capital raising. Security Code: VHL | 18/11/2013 |
releases Annual Report for the Year Ended 30 June 2013, Half Yearly Report for the period ended 31 December 2012 and Annual Report for the Year Ended 30 June 2012 | 14/11/2013 |
company is no longer in administration | 13/11/2013 |
in accordance with the Prospectus dated 19 September 2013, the Company has had significant interest in the capital raising and has received subscriptions well in excess of the proposed maximum $2,500,000 capital raising | 25/10/2013 |
issues a prospectus for the offer of 25 million First Placement Shares at an issue price of $0.00001 per Share to raise $250 and 100 million First Placement Options at an issue price of $0.00001 per First Placement Option to raise $1,000 (together the First Placement) and For the offer of a minimum of 360,000,000 Second Placement Shares and up to a maximum of 140,000,000 additional Second Placement Shares, at an issue price of $0.005 per Share to raise at least $1,800,000 or up to a maximum of $2,500,000 | 19/09/2013 |
it is our understanding a share consolidation is about to take place whereby 10 existing shares are consolidated into one share | 03/09/2013 |
executes a reconstruction deed | 26/02/2013 |
the company is to enter into a Deed of Company Arrangement | 12/10/2012 |
Directors today appointed Mr. Laurie A Fitzgerald and Mr. Stephen R Dixon of Grant Thornton as Voluntary Administrators of the Company | 24/08/2012 |
The directors of the Company request the continuation of the suspension of the Company's securities from official quotation. The Company is to make an announcement shortly concerning the termination of the Share Sale Agreement with the vendors of 4G Vaccines Pty Ltd | 14/06/2012 |
provides an update on Transgene" clinical program TG4001 (HPV therapeutic vaccine). This project utilises Co-X-GeneTM technology and is the subject of a license agreement between Transgene and Virax | 14/05/2012 |
at the Noteholder General Meeting of Virax Holdings Limited the resolutions to amend to terms of the Convertible Notes were passed | 30/03/2012 |
releases copies of the Notice of Meeting, Proxy Form and Information Memorandum for the Noteholder General Meeting to be held on Friday 30 March 2012 at Quest Beaumont Kew, 7 Studley Park Road, Kew at 2.00 pm - ASX Code - VHLG | 15/03/2012 |
suspended following failure to lodge financial reports | 01/03/2012 |
the unsecured convertible notes (the "Notes") of Virax Holdings Limited (the "Company") will be suspended from quotation at the close of trading on 21 December 2011, pending their maturity on 31 December 2011. For details of a proposal to extend the maturity date of the Notes to 31 March 2012, please refer to the Company's notice of meeting lodged on ASX on 12 December 2011. Security Code: VHLG Please note the suspension only applies to the Notes and not to the Company's other quoted securities | 21/12/2011 |
name changed from Rancoo Limited | 24/03/1997 |
Your browser may reflect a date of printing in American format.
| Time to update the share registry details for Virax | 13/05/2014 19:21:42 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Wayne Millen | Executive Chairman | 02/09/2013 |
| Steven Engle | Non Exec Chairman | 28/11/2014 |
| Rob Crombie | Managing Director | 16/06/2014 |
| Larry Ward | CEO | 20/12/2007 |
| Steven Yatomi-Clarke | Non Exec Director | 28/11/2014 |
| Roland Toder | Non Exec Director | 02/09/2013 |
| Albert King | Non Exec Director | 16/01/2008 |
| Brendan de Kauwe | Non Exec Director | 02/09/2013 |
| James Campbell | Non Exec Director | 28/11/2014 |
| Paul Hopper | Executive Director | 30/05/2014 |
| Sean Henbury | Company Secretary |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|---|---|---|
| Michael Humphris | Chairman, Non Exec Director | 16/01/2008 | 02/09/2013 |
| Ian Pyman | Non Exec Director | 16/01/2008 | 02/09/2013 |
| John Morrison | Director, CFO | 13/03/2012 | 02/09/2013 |
Date of first appointment, title may have changed.
Contact Us | Financial Services Guide | Privacy Policy
This website is owned and operated by Investogain Pty Limited.
ABN 88 129 443 447 | AFSL 334036
Information provided is of a general nature and not for trading or advice.
Copyright © 2002-2025 Investogain Pty Limited. All rights reserved.
